top of page

Promising Covid-19 vaccination data from Moderna

This week, the news hit that another clinical trial for a Covid-19 vaccine (known as mRNA-1273) has shown promising interim results after an independent data and safety monitoring board (DSMB) reviewed the trial data and shared its interim analysis. The news comes only one week after Pfizer had announced their preliminary trial results which suggest that their vaccine has 90% efficiency.

The mRNA-1273 vaccine was co-developed by the Cambridge, Massachusetts-based biotechnology company Moderna, Inc., together with the National Institute of Allergy and Infectious Diseases (NIAID), which belongs to the National Institute of Health. The vaccine combines Moderna’s mRNA (messenger RNA) delivery platform with the stabilized SARS-CoV-2 spike immunogen (S-2P) developed by NIAID.

The review of the board suggests the safety and effectiveness of the vaccine to prevent symptomatic Covid-19 in adults. These results are based on 95 cases of symptomatic Covid-19, which showed that the vaccine was received well and was tolerated among the volunteers. The review also suggested that the vaccine had an efficacy rate of 94.5%, which is 4.5% more than what the clinical trial of Pfizer suggested.

The phase 3 clinical trial study was launched in July 2020 and is currently conducted with more than 30,000 participants at 100 different clinical research sites in the United States. Results from earlier studies indicated that the vaccine was tolerated well and immunogenic for candidates. The study ensured to work with a very representative sample of participants due to the disproportionate impact of the epidemic on underrepresented minority populations. Therefore, 37% of enrolled clinical trial volunteers are from racial and ethnic minorities to ensure the safety of the vaccine for everybody.

Partner with accredited companies

Since 2015, our team has been hard at work raising awareness of clinical trials across the globe. A Forbes ‘30 Under 30’ company and a graduate of the renowned Techstar program in New York, Citruslabs is at the forefront of patient recruitment and retention technologies. With over 3 million patients now recorded on our databases, our patient recruitment dashboard is fast becoming the most efficient method of trial recruitment.

Now a #1 health app in 17 countries, our Mindmate app is helping to revolutionize the way we think about healthcare. Mindmate “[takes] senior care into the digital age” (Forbes, 2018) by providing people with the cognitive decline the essential tools to help them rebuild and maintain strong mental health. Trusted by millions of users, our health community continues to grow as the content available expands to the needs of individuals today.

With more than 200 research sites now using the Citrus platform to screen thousands of patients every month, researchers are now well on their way to finding new treatments for hundreds of different health conditions - something that just would not be possible without a technological solution. Make sure that your clinical trial is in the lucky 12% and turn that luck into guaranteed results with Citrus.

  • Interested in finding out more? Get in touch with us here, and check out our archives for all our top tips and tricks on running successful clinical trials in today's constantly changing industry.

Still a little unsure? Check out what our customers have to say about us here.


bottom of page